Show simple item record

dc.contributor.authorMarkewitz, Robert
dc.contributor.authorTorge, Antje
dc.contributor.authorWandinger, Klaus-Peter
dc.contributor.authorPauli, Daniela
dc.contributor.authorDargvainiene, Justina
dc.contributor.authorFranke, Andre
dc.contributor.authorBujanda Fernández de Pierola, Luis ORCID
dc.contributor.authorMarimón Ortiz de Zarate, José María
dc.contributor.authorBañales Asurmendi, Jesús María ORCID
dc.contributor.authorGutiérrez Stampa, María Angeles
dc.contributor.authorNafría, Beatriz
dc.contributor.authorJunker, Ralf
dc.date.accessioned2021-09-24T12:22:56Z
dc.date.available2021-09-24T12:22:56Z
dc.date.issued2021-07-14
dc.identifier.citationDiseases 110 : 114-122 (2021)es_ES
dc.identifier.issn1878-3511
dc.identifier.urihttp://hdl.handle.net/10810/53138
dc.description.abstractOBJECTIVES: To examine the relationship between antibody status and cycle threshold (Ct) values, the prognostic value of the latter for COVID-19 patients, and the inter-assay comparability of SARS-CoV-2 Ct values. METHODS: In 347 COVID-19 inpatients, SARS-CoV-2 Ct values (via reverse transcription-quantitative polymerase chain reaction) on admission were compared between 2 assays and correlated with the antibody response (in the course of the disease), the clinical course and the time since onset of symptoms. RESULTS: Ct values for 2 of 3 target genes showed significant differences between the 2 assays used (P=0.012 and P<0.0001). Ct values were significantly higher for antibody positive patients (P<0.0001) and positively correlated with the amount of time since onset of symptoms (R: 0.332-0.363; P<0.001). Patients with fatal outcomes showed higher viral loads than survivors (P<0.0001). CONCLUSIONS: Ct values depend strongly on assay used and target gene examined and should not be used as quantitative values to guide therapeutic or diagnostic decisions. The inverse association between antibody status and viral load suggests that antibodies contribute to the elimination of the virus, independent of the outcome, which is influenced by the viral load on admission and might depend more strongly on other parts of the immune response.es_ES
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/*
dc.subjectCOVID-19es_ES
dc.subjectCt valuees_ES
dc.subjectRT-qPCRes_ES
dc.subjectSARS-CoV-2es_ES
dc.subjectanti-SARS-CoV-2 antibodieses_ES
dc.titleAnalysis of SARS-CoV-2 reverse transcription-quantitative polymerase chain reaction cycle threshold values vis-à-vis anti-SARS-CoV-2 antibodies from a high incidence regiones_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.holder2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )es_ES
dc.rights.holderAtribución-NoComercial-SinDerivadas 3.0 España*
dc.relation.publisherversionhttps://www.sciencedirect.com/science/article/pii/S1201971221005701?via%3Dihubes_ES
dc.identifier.doi10.1016/j.ijid.2021.07.014
dc.departamentoesMedicinaes_ES
dc.departamentoeuMedikuntzaes_ES


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )
Except where otherwise noted, this item's license is described as 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )